Metastatic breast cancer patient perceptions of somatic tumor genomic testing

Elizabeth J. Adams; Sarah Asad; Raquel Reinbolt; Katharine A. Collier; Mahmoud Abdel-Rasoul; Susan Gillespie; James L. Chen; Mathew A. Cherian; Anne M. Noonan; Sagar Sardesai; Jeffrey Vandeusen; Robert Wesolowski; Nicole Williams; Charles L. Shapiro; Erin R. Macrae; Robert Pilarski; Amanda E. Toland; Leigha Senter; Bhuvaneswari Ramaswamy; Clara N. Lee; Maryam B. Lustberg; Daniel G. Stover

doi:10.1186/s12885-020-06905-2

Metastatic breast cancer patient perceptions of somatic tumor genomic testing

Elizabeth J. Adams, Sarah Asad, Raquel Reinbolt, Katharine A. Collier, Mahmoud Abdel-Rasoul, Susan Gillespie, James L. Chen, Mathew A. Cherian, Anne M. Noonan, Sagar Sardesai, Jeffrey Vandeusen, Robert Wesolowski, Nicole Williams, Charles L. Shapiro, Erin R. Macrae, Robert Pilarski, Amanda E. Toland, Leigha Senter, Bhuvaneswari Ramaswamy, Clara N. LeeMaryam B. Lustberg, Daniel G. Stover

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Background: To assess metastatic breast cancer (MBC) patient psychological factors, perceptions, and comprehension of tumor genomic testing. Methods: In a prospective, single institution, single-arm trial, patients with MBC underwent next-generation sequencing at study entry with sequencing results released at progression. Patients who completed surveys before undergoing sequencing were included in the present secondary analysis (n = 58). We administered four validated psychosocial measures: Center for Epidemiologic Studies Depression Scale, Beck Anxiety Inventory, Trust in Physician Scale, and Communication and Attitudinal Self-Efficacy scale for Cancer. Genetic comprehension was assessed using 7-question objective and 6-question subjective measures. Longitudinal data were assessed (n = 40) using paired Wilcoxon signed rank and McNemar's test of agreement. Results: There were no significant differences between the beginning and end of study in depression, anxiety, physician trust, or self-efficacy (median time on study: 7.6 months). Depression and anxiety were positively associated with each other and both negatively associated with self-efficacy. Self-efficacy decreased from pre- to post-genomic testing (p = 0.05). Objective genetics comprehension did not significantly change from pre- to post-genomic testing, but patients expressed increased confidence in their ability to teach others about genetics (p = 0.04). Objective comprehension was significantly lower in non-white patients (p = 0.02) and patients with lower income (p = 0.04). Conclusions: This is the only study, to our knowledge, to longitudinally evaluate multiple psychological metrics in MBC as patients undergo tumor genomic testing. Overall, psychological dimensions remained stable over the duration of tumor genomic testing. Among patients with MBC, depression and anxiety metrics were negatively correlated with patient self-efficacy. Patients undergoing somatic genomic testing had limited genomic knowledge, which varied by demographic groups and may warrant additional educational intervention. Clinical trial information: NCT01987726, registered November 13, 2013.

Original language	English
Article number	389
Journal	BMC Cancer
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s12885-020-06905-2
State	Published - 6 May 2020
Externally published	Yes

Keywords

Genomics
Metastatic breast cancer

Access to Document

10.1186/s12885-020-06905-2

Cite this

Adams, E. J., Asad, S., Reinbolt, R., Collier, K. A., Abdel-Rasoul, M., Gillespie, S., Chen, J. L., Cherian, M. A., Noonan, A. M., Sardesai, S., Vandeusen, J., Wesolowski, R., Williams, N., Shapiro, C. L., Macrae, E. R., Pilarski, R., Toland, A. E., Senter, L., Ramaswamy, B., ... Stover, D. G. (2020). Metastatic breast cancer patient perceptions of somatic tumor genomic testing. BMC Cancer, 20(1), Article 389. https://doi.org/10.1186/s12885-020-06905-2

@article{c5ac0487cc3342fcb50ecad0ba21eb4a,

title = "Metastatic breast cancer patient perceptions of somatic tumor genomic testing",

abstract = "Background: To assess metastatic breast cancer (MBC) patient psychological factors, perceptions, and comprehension of tumor genomic testing. Methods: In a prospective, single institution, single-arm trial, patients with MBC underwent next-generation sequencing at study entry with sequencing results released at progression. Patients who completed surveys before undergoing sequencing were included in the present secondary analysis (n = 58). We administered four validated psychosocial measures: Center for Epidemiologic Studies Depression Scale, Beck Anxiety Inventory, Trust in Physician Scale, and Communication and Attitudinal Self-Efficacy scale for Cancer. Genetic comprehension was assessed using 7-question objective and 6-question subjective measures. Longitudinal data were assessed (n = 40) using paired Wilcoxon signed rank and McNemar's test of agreement. Results: There were no significant differences between the beginning and end of study in depression, anxiety, physician trust, or self-efficacy (median time on study: 7.6 months). Depression and anxiety were positively associated with each other and both negatively associated with self-efficacy. Self-efficacy decreased from pre- to post-genomic testing (p = 0.05). Objective genetics comprehension did not significantly change from pre- to post-genomic testing, but patients expressed increased confidence in their ability to teach others about genetics (p = 0.04). Objective comprehension was significantly lower in non-white patients (p = 0.02) and patients with lower income (p = 0.04). Conclusions: This is the only study, to our knowledge, to longitudinally evaluate multiple psychological metrics in MBC as patients undergo tumor genomic testing. Overall, psychological dimensions remained stable over the duration of tumor genomic testing. Among patients with MBC, depression and anxiety metrics were negatively correlated with patient self-efficacy. Patients undergoing somatic genomic testing had limited genomic knowledge, which varied by demographic groups and may warrant additional educational intervention. Clinical trial information: NCT01987726, registered November 13, 2013.",

keywords = "Genomics, Metastatic breast cancer",

author = "Adams, {Elizabeth J.} and Sarah Asad and Raquel Reinbolt and Collier, {Katharine A.} and Mahmoud Abdel-Rasoul and Susan Gillespie and Chen, {James L.} and Cherian, {Mathew A.} and Noonan, {Anne M.} and Sagar Sardesai and Jeffrey Vandeusen and Robert Wesolowski and Nicole Williams and Shapiro, {Charles L.} and Macrae, {Erin R.} and Robert Pilarski and Toland, {Amanda E.} and Leigha Senter and Bhuvaneswari Ramaswamy and Lee, {Clara N.} and Lustberg, {Maryam B.} and Stover, {Daniel G.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = may,

day = "6",

doi = "10.1186/s12885-020-06905-2",

language = "English",

volume = "20",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

number = "1",

}

Adams, EJ, Asad, S, Reinbolt, R, Collier, KA, Abdel-Rasoul, M, Gillespie, S, Chen, JL, Cherian, MA, Noonan, AM, Sardesai, S, Vandeusen, J, Wesolowski, R, Williams, N, Shapiro, CL, Macrae, ER, Pilarski, R, Toland, AE, Senter, L, Ramaswamy, B, Lee, CN, Lustberg, MB & Stover, DG 2020, 'Metastatic breast cancer patient perceptions of somatic tumor genomic testing', BMC Cancer, vol. 20, no. 1, 389. https://doi.org/10.1186/s12885-020-06905-2

TY - JOUR

T1 - Metastatic breast cancer patient perceptions of somatic tumor genomic testing

AU - Adams, Elizabeth J.

AU - Asad, Sarah

AU - Reinbolt, Raquel

AU - Collier, Katharine A.

AU - Abdel-Rasoul, Mahmoud

AU - Gillespie, Susan

AU - Chen, James L.

AU - Cherian, Mathew A.

AU - Noonan, Anne M.

AU - Sardesai, Sagar

AU - Vandeusen, Jeffrey

AU - Wesolowski, Robert

AU - Williams, Nicole

AU - Shapiro, Charles L.

AU - Macrae, Erin R.

AU - Pilarski, Robert

AU - Toland, Amanda E.

AU - Senter, Leigha

AU - Ramaswamy, Bhuvaneswari

AU - Lee, Clara N.

AU - Lustberg, Maryam B.

AU - Stover, Daniel G.

PY - 2020/5/6

Y1 - 2020/5/6

N2 - Background: To assess metastatic breast cancer (MBC) patient psychological factors, perceptions, and comprehension of tumor genomic testing. Methods: In a prospective, single institution, single-arm trial, patients with MBC underwent next-generation sequencing at study entry with sequencing results released at progression. Patients who completed surveys before undergoing sequencing were included in the present secondary analysis (n = 58). We administered four validated psychosocial measures: Center for Epidemiologic Studies Depression Scale, Beck Anxiety Inventory, Trust in Physician Scale, and Communication and Attitudinal Self-Efficacy scale for Cancer. Genetic comprehension was assessed using 7-question objective and 6-question subjective measures. Longitudinal data were assessed (n = 40) using paired Wilcoxon signed rank and McNemar's test of agreement. Results: There were no significant differences between the beginning and end of study in depression, anxiety, physician trust, or self-efficacy (median time on study: 7.6 months). Depression and anxiety were positively associated with each other and both negatively associated with self-efficacy. Self-efficacy decreased from pre- to post-genomic testing (p = 0.05). Objective genetics comprehension did not significantly change from pre- to post-genomic testing, but patients expressed increased confidence in their ability to teach others about genetics (p = 0.04). Objective comprehension was significantly lower in non-white patients (p = 0.02) and patients with lower income (p = 0.04). Conclusions: This is the only study, to our knowledge, to longitudinally evaluate multiple psychological metrics in MBC as patients undergo tumor genomic testing. Overall, psychological dimensions remained stable over the duration of tumor genomic testing. Among patients with MBC, depression and anxiety metrics were negatively correlated with patient self-efficacy. Patients undergoing somatic genomic testing had limited genomic knowledge, which varied by demographic groups and may warrant additional educational intervention. Clinical trial information: NCT01987726, registered November 13, 2013.

AB - Background: To assess metastatic breast cancer (MBC) patient psychological factors, perceptions, and comprehension of tumor genomic testing. Methods: In a prospective, single institution, single-arm trial, patients with MBC underwent next-generation sequencing at study entry with sequencing results released at progression. Patients who completed surveys before undergoing sequencing were included in the present secondary analysis (n = 58). We administered four validated psychosocial measures: Center for Epidemiologic Studies Depression Scale, Beck Anxiety Inventory, Trust in Physician Scale, and Communication and Attitudinal Self-Efficacy scale for Cancer. Genetic comprehension was assessed using 7-question objective and 6-question subjective measures. Longitudinal data were assessed (n = 40) using paired Wilcoxon signed rank and McNemar's test of agreement. Results: There were no significant differences between the beginning and end of study in depression, anxiety, physician trust, or self-efficacy (median time on study: 7.6 months). Depression and anxiety were positively associated with each other and both negatively associated with self-efficacy. Self-efficacy decreased from pre- to post-genomic testing (p = 0.05). Objective genetics comprehension did not significantly change from pre- to post-genomic testing, but patients expressed increased confidence in their ability to teach others about genetics (p = 0.04). Objective comprehension was significantly lower in non-white patients (p = 0.02) and patients with lower income (p = 0.04). Conclusions: This is the only study, to our knowledge, to longitudinally evaluate multiple psychological metrics in MBC as patients undergo tumor genomic testing. Overall, psychological dimensions remained stable over the duration of tumor genomic testing. Among patients with MBC, depression and anxiety metrics were negatively correlated with patient self-efficacy. Patients undergoing somatic genomic testing had limited genomic knowledge, which varied by demographic groups and may warrant additional educational intervention. Clinical trial information: NCT01987726, registered November 13, 2013.

KW - Genomics

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85084389015&partnerID=8YFLogxK

U2 - 10.1186/s12885-020-06905-2

DO - 10.1186/s12885-020-06905-2

M3 - Article

C2 - 32375690

AN - SCOPUS:85084389015

SN - 1471-2407

VL - 20

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 389

ER -

Metastatic breast cancer patient perceptions of somatic tumor genomic testing

Abstract

Keywords

Access to Document

Fingerprint

Cite this